54 completed. 54 Phase 2, 8 Phase 3, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 54 | Completed 54 |
| Phase 3 | 8 | Completed 8 |
| Phase 1 | 6 | Completed 6 |
Follow Prostatic Hyperplasia: new trials by email Literature Review of Prostatic Hyperplasia trials Research Report on Prostatic Hyperplasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RADA16 for Aquablation Day Case PuraStat - Hematuria, Benign Prostatic Hyperplasia | Phase 2 | Completed | NYU Langone Health | 24 | 2026-05-14 | 2026-11-09 |
| The Additive Value of Pyridostigmine to Silodosin in Acute Urinary Retention silodosin 8 mg capsule and the pyridostigmine bromide 60 mg tablet, silodosin 8 mg capsule - Prostatic Hyperplasia | Phase 2 | Completed | Beni-Suef University | 140 | 2023-02-01 | 2024-03-20 |
| The Effectiveness of Spermotrend Food Supplement in the Treatment of Male Infertility Spermotrend - Male Infertility, Benign Prostatic Hyperplasia | Phase 2 / Phase 3 | Completed | Catalysis SL | 150 | 2021-06-15 | 2023-03-28 |
| Teverelix Evaluated in Advanced Prostate Cancer teverelix TFA 120 mg, teverelix TFA 180 mg - Prostatic Adenoma | Phase 2 | Completed | Antev Ltd. | 50 | 2021-03-04 | 2024-07-23 |
| Composite Steep-pulseTreatment Device Used in Patients With Benign Prostatic Hyperplasia Composite Steep-pulse Treatment Device, Tamsulosin Hydrochloride Capsules - Benign Prostatic Hyperplasia | Phase 2 / Phase 3 | Completed | REMD Medical Technology | 160 | 2020-08-20 | 2022-09-07 |
| The Effect of Traditional Chinese Medicine on Benign Prostatic Hyperplasia VGH-BPH1, Placebo (Corn starch pill manufactured to mimic VGH-BPH1) - Benign Prostatic Hyperplasia | Phase 1 / Phase 2 | Completed | Taipei Veterans General Hospital, Taiwan | 23 | 2019-03-06 | 2020-04-13 |
| Optilume⢠BPH Prostatic Drug Coated Balloon Dilation Catheter Optilume⢠BPH Prostatic DCB Dilation Catheter, Paclitaxel - Benign Prostatic Hyperplasia, Benign Prostatic Hypertrophy | Phase 2 | Completed | Urotronic Inc. | 80 | 2017-12-19 | 2025-11-26 |
| Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH) Fedovapagon 2 mg, Placebo - Nocturia | Phase 2 / Phase 3 | Completed | Vantia Ltd | 432 | 2016-03-01 | 2018-10-31 |
| A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH Placebo, GV1001 - Benign Prostatic Hyperplasia (BPH) | Phase 2 | Completed | GemVax & Kael | 161 | 2015-10-01 | 2022-03-04 |
| A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia talaporfin sodium, Saline, Drug Activator 100 J/cm - Benign Prostatic Hyperplasia | Phase 2 | Completed | Light Sciences Oncology | 225 | 2014-11-01 | 2018-08-08 |
| Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia WC3055, Placebo - Benign Prostatic Hyperplasia | Phase 2 | Completed | Warner Chilcott | 796 | 2013-08-01 | 2015-06-29 |
| Prostate Embolization for Benign Prostatic Hyperplasia Prostatic Embolization with Embosphere Micropsheres - Benign Prostatic Hyperplasia | Phase 1 / Phase 2 | Completed | James B. Spies, MD | 15 | 2013-08-01 | 2019-12-10 |
| A Study to Evaluate the Efficacy and Safety of ASP4901 in Patients With Benign Prostate Hyperplasia ASP4901, Tamsulosin, Placebo - Benign Prostate Hyperplasia | Phase 2 | Completed | Astellas Pharma Inc | 320 | 2013-07-22 | 2024-11-06 |
| Prostatic Artery Embolization for Benign Prostatic Hyperplasia Prostate artery embolization - Benign Prostate Hyperplasia | Phase 2 / Phase 3 | Completed | Saskatchewan Health Authority - Regina Area | 13 | 2013-03-01 | 2016-04-07 |
| Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) Levels Doxazosin 4 mg daily plus Celecoxib 200 mg every day (QD), Doxazosin 4 mg every day (QD) - Benign Prostatic Hyperplasia | Phase 2 | Completed | Buddhist Tzu Chi General Hospital | 140 | 2012-08-01 | 2014-07-15 |
| Effectiveness of onaBoNT-A vs Oral Tamsulosin in Men With BPH and LUTS onaBoNT-A + placebo, Tamsulosin + placebo - Benign Prostatic Hyperplasia, Lower Urinary Track Symptoms | Phase 2 | Completed | VA Office of Research and Development | 63 | 2012-06-01 | 2021-10-05 |
| Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy Degarelix - Prostate Cancer | Phase 2 | Completed | British Columbia Cancer Agency | 50 | 2012-04-01 | 2020-01-27 |
| Evaluation of Finastride Effect in Different Dosage on the Amount of Perioperative Bleeding in Transurthral Resection of Prostate TURP - Benign Prostate Hyperplasia | Phase 2 / Phase 3 | Completed | Shiraz University of Medical Sciences | 60 | 2012-01-01 | 2016-04-20 |
| Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH) PRX302, Placebo - Benign Prostatic Hyperplasia | Phase 1 / Phase 2 | Completed | Sophiris Bio Corp | 40 | 2011-09-01 | 2013-08-21 |
| An Efficacy Trial of Electroacupuncture at Points of Bilateral BL33 for Mild and Moderate Benign Prostatic Hyperplasia needle - Benign Prostatic Hyperplasia (BPH) | Phase 2 | Completed | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | 100 | 2010-09-01 | 2013-05-27 |
Showing 20 of 54. Sign in to see all of them.
Lower Urinary Tract Symptoms (7) · Nocturia (2) · Prostatic Neoplasms (2) · Eunuchism (1) · Genital Diseases (1) · Hematuria (1) · Infertility, Male (1) · Lymphoma, Follicular (1) · Muscular Atrophy (1) · Prostatic Diseases (1) · Prostatism (1) · Prostatitis (1) · Sarcopenia (1)
Genital Diseases, Male (54) · Male Urogenital Diseases (54) · Urogenital Diseases (54) · Genital Diseases (53) · Prostatic Diseases (53) · Pathological Conditions, Signs and Symptoms (11) · Signs and Symptoms (11) · Urological Manifestations (10) · Lower Urinary Tract Symptoms (3) · Neoplasms (3) · Genital Neoplasms, Male (2) · Neoplasms by Site (2) · Urogenital Neoplasms (2) · Atrophy (1) · Endocrine System Diseases (1)
Tamsulosin (7) · Botulinum Toxins, Type A (6) · Tadalafil (5) · Saline Solution (3) · silodosin (3) · 1-(6-ethoxy-5-(3-ethyl-6,7-dihydro-2-(2-methoxyethyl)-7-oxo-2H-pyrazolo(4,3-d)pyrimidin-5-yl)-3-pyridyl sulphonyl)-4-ethylpiperazine (2) · Finasteride (2) · PRX302 (2) · Sodium Chloride (2) · Talaporfin (2) · Transurethral Resection of Prostate (2) · Vardenafil Dihydrochloride (2) · acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (2) · Acupuncture Therapy (1) · Celecoxib (1)
Eli Lilly and Company (5) · Allergan (3) · Astellas Pharma Inc (2) · Bayer (2) · Light Sciences Oncology (2) · Pfizer (2) · Sophiris Bio Corp (2) · VA Office of Research and Development (2) · American Medical Systems (1) · Antev Ltd. (1) · Ausio Pharmaceuticals, LLC (1) · Beni-Suef University (1) · Boehringer Ingelheim (1) · British Columbia Cancer Agency (1) · Buddhist Tzu Chi General Hospital (1)
United States (22) · Canada (8) · Germany (6) · South Korea (5) · Czechia (4) · Japan (4) · Slovakia (4) · Australia (3) · France (3) · Italy (3) · Poland (3) · Taiwan (3) · United Kingdom (3) · Austria (2) · China (2)
Albertas Ulys, MD (1) · Allan J Pantuck, MD, MS, FACS (1) · Christopher Kelly, MD (1) · Christopher P Smith, MD (1) · Donald Bergner, MD (1) · Hann-Chorng Kuo, M.D. (1) · Herman Ellman, MD (1)
PMID 21791356, PMID 12893330, PMID 15126771, PMID 18461049, PMID 18722631, PMID 19409693, PMID 20163842, PMID 21943105, PMID 23098762, PMID 23537687, PMID 23593139, PMID 24012740, PMID 24326421, PMID 25873370, PMID 26299520, PMID 26945662, PMID 27842331, PMID 28053292, PMID 29228755, PMID 29398594, PMID 37354260, PMID 38311868
U01DK060817 (1)